Accueil - CRCL-Plasticité tumorale dans le mélanome

Antonio Farina, Macarena Villagrán-García, Anthony Fourier, Anne-Laurie Pinto, Fatima Chorfa, et al.. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study. The Lancet Regional Health - Europe, 2024, 44, pp.101011. ⟨10.1016/j.lanepe.2024.101011⟩. ⟨hal-04796087⟩
Simon Durand, Yaqi Tang, Roxane M Pommier, Valentin Benboubker, Maxime Grimont, et al.. ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions. Oncogene, In press, ⟨10.1038/s41388-024-03010-7⟩. ⟨hal-04526523⟩
Gaël Runel, Noémie Lopez-Ramirez, Laetitia Barbollat-Boutrand, Muriel Cario, Simon Durand, et al.. Cancer Cell Biomechanical Properties Accompany Tspan8-Dependent Cutaneous Melanoma Invasion. Cancers, 2024, 16 (4), pp.694. ⟨10.3390/cancers16040694⟩. ⟨hal-04504695⟩
Stéphane Dalle, Estelle Verronese, Axelle N’kodia, Christine Bardin, Céline Rodriguez, et al.. Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients. OncoImmunology, 2024, 13 (1), pp.2372118. ⟨10.1080/2162402X.2024.2372118⟩. ⟨hal-04632685⟩
Delphine Bredel, Edi Tihic, Séverine Mouraud, François-Xavier Danlos, Sandrine Susini, et al.. Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers. Journal of experimental & clinical cancer research, 2023, 42, ⟨10.1186/s13046-023-02897-6⟩. ⟨hal-04431918⟩
Philip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret Mcgrath, et al.. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Journal for Immunotherapy of Cancer, 2023, 11, ⟨10.1136/jitc-2023-007637⟩. ⟨hal-04941902⟩

Derniers manuscrits de l'équipe

Chiffres clés